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Abstract Laninamivir octanoate, a long-acting neur-
aminidase inhibitor, is an effective treatment for inﬂuenza.
However, its effectiveness for the prevention of inﬂuenza
has not yet been demonstrated. We conducted a double-
blind, multicenter, randomized, placebo-controlled trial to
determine whether laninamivir octanoate was superior to a
placebo for post-exposure prophylaxis of inﬂuenza in
household contacts. Eligible participants, who were
household members who did not have inﬂuenza and were
in contact with an inﬂuenza-infected index patient, were
randomly assigned (1:1:1) to one of three groups: 20 mg of
laninamivir octanoate once daily for 2 days (LO-2), 20 mg
of laninamivir octanoate once daily for 3 days (LO-3), or a
placebo. The primary endpoint was the proportion of par-
ticipants who developed clinical inﬂuenza during a 10-day
period. A total of 1711 participants were enrolled, and
1451 participants were included in the primary analysis.
The proportion of participants with clinical inﬂuenza was
3.9 % (19/487) in the LO-2 group, 3.7 % (18/486) in the
LO-3 group, and 16.9 % (81/478) in the placebo group
(P\ 0.001 for each of the laninamivir octanoate group).
The relative risk reductions, compared with the placebo
group, were 77.0 % [95 % conﬁdence interval (CI)
62.7–85.8] and 78.1 % (95 % CI 64.1–86.7 %) for the LO-
2 and LO-3 groups, respectively. The incidences of adverse
events in the laninamivir octanoate groups were similar to
that in the placebo group. The inhalation of 20 mg of
laninamivir octanoate once daily for 2 or 3 days was well
tolerated and effectively prevented the development of
inﬂuenza in household contacts.
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Introduction
The family unit is a major source for the transmission of
inﬂuenza viruses; the incidence of inﬂuenza in household
contacts is higher than in the general population [1].
Although the primary means of inﬂuenza prevention is
vaccination, anti-inﬂuenza drugs play an important role in
preventing inﬂuenza among persons with a high risk of
infection, such as household contacts [2], if a vaccine is not
available, if exposure occurs before the vaccine has
induced an immune response, or if there is no immune
response to the vaccination. The efﬁcacy of neuraminidase
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inhibitors, such as oseltamivir and zanamivir, for the pre-
vention of inﬂuenza has been established [3–9].
Laninamivir potently inhibits the neuraminidase activi-
ties of various inﬂuenza A and B viruses, including sub-
types N1–N9, inﬂuenza A(H1N1)pdm09 viruses, highly
pathogenic avian inﬂuenza H5N1 viruses, and oseltamivir-
resistant viruses [10, 11]. The efﬁcacy of a single inhala-
tion of laninamivir octanoate for inﬂuenza treatment in
adults and children has been demonstrated [12–14]. In
addition, studies in mice have shown the protective efﬁcacy
of the intranasal administration of laninamivir octanoate
prior to virus infection [10].
We conducted a randomized placebo-controlled trial
during the 2009 inﬂuenza pandemic season to evaluate the
efﬁcacy of the inhalation of 20 or 40 mg of laninamivir
octanoate once a week (Days 1 and 8) for the post-exposure
prophylaxis of inﬂuenza in household contacts during a
10-day period (unpublished data; registration number,
JapicCTI-090941). The proportion of participants with
clinical inﬂuenza, which was regarded as the primary
endpoint, was 3.6 % (7/197) in the 20 mg group, 3.7 % (7/
188) in the 40 mg group, and 6.6 % (12/183) in the placebo
group. The protective efﬁcacy was 45.8 % [95 % conﬁ-
dence interval (CI) -34.6 to 78.2 %] in the 20 mg group
and 43.2 % (95 % CI -41.0 to 77.1 %) in the 40 mg
group, and no signiﬁcant difference was seen. However, in
participants aged 10–19 years, among whom the trans-
missibility of the inﬂuenza A(H1N1)pdm09 virus was
reportedly high, the protective efﬁcacy seemed to be rela-
tively higher.
Therefore, we conducted a trial to evaluate the efﬁcacy
of the inhalation of 20 mg of laninamivir octanoate once
daily for 2 or 3 days for preventing the development of
inﬂuenza in household contacts. In this trial, the laninam-
ivir octanoate regimens were adjusted for a higher efﬁcacy,
since the prophylactic ability of laninamivir octanoate was
insufﬁcient at several days after the ﬁrst dose of laninam-
ivir octanoate in the previous trial.
Patients and methods
Trial design and population
This multicenter, double-blind, randomized, placebo-con-
trolled trial was conducted between November 2011 and
April 2012 at 80 primary care clinics in Japan. The trial
was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practices [15]. The protocol
was reviewed and approved by all applicable ethics and
regulatory committees. All the index patients and the par-
ticipants provided written informed consent.
Eligible participants were household members who had
been in contact with the index patient within 48 h of
symptom onset. An index patient was deﬁned as someone
who was infected with inﬂuenza A or B virus. The infec-
tion in the index patient was diagnosed using a rapid
diagnostic kit. Participants were enrolled in the trial if they
were found not to have inﬂuenza, had an axillary temper-
ature of 36.9 C or lower, had no inﬂuenza-like symptoms,
and were at least 10 years old at the time of enrollment.
The exclusion criteria were as follows: infection of other
family members in addition to the index patient, an inﬂu-
enza vaccination, severe renal dysfunction, history of
hypersensitivity to neuraminidase inhibitors, treatment
with corticosteroid or other immunosuppressant, or treat-
ment with a neuraminidase inhibitor within 4 weeks.
Pregnant women, lactating women, and women who
wished to become pregnant during the trial were also
excluded in consideration of the safety of the participants
and the next generation.
Randomization and blinding
Participants were randomly assigned to one of the three
treatments in a 1:1:1 ratio on an individual basis: The
treatment groups were as follows: 20 mg of laninamivir
octanoate administered once daily for 2 days (LO-2),
20 mg of laninamivir octanoate administered once daily for
3 days (LO-3), or a placebo. The LO-2 group was treated
with 20 mg of laninamivir octanoate on Days 1 and 2 and
with the placebo on Day 3. The LO-3 group was treated
with 20 mg of laninamivir octanoate on Days 1, 2, and 3.
The placebo group was treated with the placebo on Days 1,
2, and 3. Laninamivir octanoate or an identically packaged
placebo, both containing lactose as the principal base, was
administered by self-activated inhalation. A computer-
generated block random allocation sequence was provided
by Acronet Corporation (Tokyo, Japan) and was stratiﬁed
according to the institution and whether the index patient
was infected with inﬂuenza A or B virus. If the eligibility
of the participant was conﬁrmed, the investigator accessed
the electronic data capture system and was notiﬁed of the
allocation number of the test drug, which was individually
packaged and numbered. The participants, index patients,
investigators, and trial personnel were blinded to the group
assignment throughout the trial.
Trial procedures
The evaluation period for the study drug was set at 10 days
in view of the duration of inﬂuenza virus excretion from
the index patients and the incubation period of the inﬂu-
enza virus infection in the participants.
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For all the index patients, anterior nose and posterior
pharyngeal throat swabs were taken on Day 1 for the
diagnosis of inﬂuenza. Inﬂuenza was screened using a
rapid diagnostic kit and was conﬁrmed using a laboratory
virological test. The treatment of the index patients was
uniﬁed to exclude any possible inﬂuence on the efﬁcacy
evaluation of the study drug. The index patients, except for
teenagers, were treated with oseltamivir; teenagers were
treated with zanamivir because the use of oseltamivir is not
approved for use in that age group in Japan.
For all the participants, anterior nose and posterior
pharyngeal throat swabs were taken on Days 1 and 11.
When participants developed inﬂuenza-like symptoms
during the trial duration (from Day 1 to Day 10), they were
requested to visit the study site immediately and swabs
were obtained for the conﬁrmation of inﬂuenza infection.
The participants who were diagnosed with inﬂuenza virus
infection at the visits were provided with appropriate
treatment and did not receive any subsequent doses of the
test drugs. Participants recorded their axillary temperature
and the severity of their inﬂuenza symptoms (headache,
myalgia/arthralgia, fatigue, chills/sweats, nasal symptoms,
sore throat, and cough) twice daily from Day 1 to Day 11.
The severity of each inﬂuenza symptom was graded into
four categories (0, absent; 1, mild; 2, moderate; 3, severe).
For efﬁcacy outcomes, the severity categories ‘‘2’’ and ‘‘3’’
were deﬁned as the presence of an inﬂuenza symptom.
Hematology, blood chemistry, and a urinalysis were per-
formed on Days 1 and 11 for the safety assessment.
Laboratory virological test
Each swab was placed in a sample tube containing viral
transport medium and was transferred to a test laboratory.
Inﬂuenza infection was conﬁrmed by determining the
inﬂuenza type and subtype based on a RT-PCR with spe-
ciﬁc primers designed from the hemagglutinin sequence of
the inﬂuenza A(H1N1)pdm09, seasonal inﬂuenza
A(H1N1), inﬂuenza A(H3N2), or inﬂuenza B viruses. The
laboratory virological test was performed at Mitsubishi
Chemical Medience (Tokyo, Japan).
Efﬁcacy outcomes
The primary endpoint was the proportion of participants
who developed clinical inﬂuenza between Days 1 and 11.
Clinical inﬂuenza was deﬁned as the presence of labora-
tory-conﬁrmed inﬂuenza, an axillary temperature of at least
37.5 C, and at least two inﬂuenza symptoms [4]. The
secondary endpoints were symptomatic inﬂuenza, asymp-
tomatic inﬂuenza, and inﬂuenza infection. Symptomatic
inﬂuenza, including clinical inﬂuenza, was deﬁned as lab-
oratory-conﬁrmed inﬂuenza accompanied by an axillary
temperature of at least 37.5 C or at least one inﬂuenza
symptom. Asymptomatic inﬂuenza was deﬁned as labora-
tory-conﬁrmed inﬂuenza accompanied by an axillary tem-
perature of lower than 37.5 C and no inﬂuenza symptoms.
Inﬂuenza infection was deﬁned as laboratory-conﬁrmed
inﬂuenza, regardless of the presence or absence of an
axillary temperature of at least 37.5 C or an inﬂuenza
symptom.
Statistical considerations
The primary population for evaluating efﬁcacy was deﬁned
as participants in the full analysis set (FAS) who were
conﬁrmed to not be infected with the inﬂuenza virus on
Day 1 and whose related index patient was conﬁrmed to be
positive for inﬂuenza virus on Day 1; such participants
were designated as FAS index-infected virus-negative at
baseline (FASIINAB). Additional analyses were conducted
for FAS index-infected (FASII) and FAS participants.
FASII was deﬁned as participants in the FAS whose related
index patient was conﬁrmed to be positive for inﬂuenza
virus on Day 1. The safety analysis included all the par-
ticipants who received at least one dose of trial treatment
and who underwent at least one safety assessment. All the
analyses were performed using SAS System Release 9.2
(SAS Institute). All the reported P values were two-sided,
and the level of signiﬁcance was P\ 0.05.
To test the trial hypothesis, we used the Fisher exact test
to compare the proportion of participants who developed
clinical inﬂuenza between each laninamivir octanoate
group and the placebo group. Multiplicity was adjusted
using the Hochberg method [16]. We also calculated the
relative risk reduction compared with the placebo as the
protective efﬁcacy and the corresponding 95 % CI. We
also analyzed symptomatic inﬂuenza, asymptomatic inﬂu-
enza, and inﬂuenza infection in the same manner as for the
primary endpoint. Additionally, we explored the consis-
tency of the treatment effect on the primary endpoint in
prespeciﬁed subgroups.
The sample size was based on the assumptions that the
protective efﬁcacy of laninamivir octanoate would be at
least 70 % and the proportion of participants who would
experience clinical inﬂuenza during the trial would be
1.65 % for the laninamivir octanoate groups and 5.5 % for
the placebo group, based on the previous prophylaxis trial
of laninamivir octanoate conducted in 2009. On this basis,
470 participants in each group were required to achieve an
80 % power to detect the superiority of laninamivir octa-
noate over the placebo.
The trial was registered with JapicCTI (JapicCTI-
111647).
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Results
Trial population
A total of 1711 participants were enrolled in the trial
(Fig. 1). Of these, 47 participants were excluded from all
analyses: three participants discontinued the trial before
receiving any treatment, informed consent was not cor-
rectly obtained from two participants, and 42 participants
treated at a trial center where the participation was halted
because of issues related to the trial procedures and reli-
ability of the data were excluded. Six other participants did
not record their inﬂuenza symptoms and were excluded
from the FAS. Of the FAS (1658 participants), 30 partic-
ipants were excluded from the FASII because the related
index patients were inﬂuenza virus-negative. In the FASII
(1628 participants), 177 participants were inﬂuenza virus-
positive at baseline and were excluded from the FASII-
NAB. A total of 1451 participants were included in the
FASIINAB (487 participants in the LO-2 group, 486 in the
LO-3 group, and 478 in the placebo group).
The baseline characteristics were well balanced among
the three groups in the FASIINAB (Table 1), the FAS, and
the FASII (data not shown). Most of the index patients
were children under the age of 15 years, whereas most of
the household contacts were the parents of index patients.
Among the index patients, 91 % were infected with inﬂu-
enza A(H3N2) virus and 9 % were infected with inﬂuenza
B virus (Table 1).
Efﬁcacy
In the FASIINAB, the proportion of participants with
clinical inﬂuenza, the primary endpoint, was 3.9 % (19/
487), 3.7 % (18/486), and 16.9 % (81/478) in the LO-2,
LO-3, and placebo groups, respectively (Table 2). Lani-
namivir octanoate signiﬁcantly reduced the proportion of
participants with clinical inﬂuenza, compared with the
placebo (P\ 0.001 for each laninamivir octanoate group).
In this respect, no signiﬁcant difference was observed
between the LO-2 and the LO-3 groups. The protective
efﬁcacies were 77.0 % (95 % CI 62.7–85.8 %) and 78.1 %
(95 % CI 64.1–86.7 %) in the LO-2 and LO-3 groups,
respectively. Similar results were also obtained in the FAS
and FASII (Table 2). In the placebo group, approximately
85 % (71/81) of the participants with clinical inﬂuenza
developed inﬂuenza between Days 1 and 5, but the inci-
dence appeared to decrease after Day 6. In contrast, lani-
namivir octanoate inhibited the development of clinical
inﬂuenza throughout the trial period in each of the lani-
namivir octanoate groups (Fig. 2).
The proportions of participants with symptomatic
inﬂuenza were 6.8 % (33/487), 6.6 % (32/486), and 20.9 %
(100/478) in the LO-2, LO-3, and placebo groups,
respectively. The proportions of participants with inﬂuenza
infection were 10.3 % (50/487), 10.3 % (50/486), and
25.5 % (122/478) in the LO-2, LO-3, and placebo groups,
respectively. Laninamivir octanoate signiﬁcantly reduced
the proportions of participants with symptomatic inﬂuenza
and the proportion of participants infected with inﬂuenza
virus, compared with the placebo (P\ 0.001 in each lan-
inamivir octanoate group).
In the subgroup of participants whose related index
patients were infected with the inﬂuenza A(H3N2) virus,
laninamivir octanoate signiﬁcantly reduced the develop-
ment of clinical inﬂuenza, compared with the placebo
(Table 3). The number of participants whose related index
patients were infected with the inﬂuenza B virus was rel-
atively small, and the trial did not have a sufﬁcient statis-
tical power to detect a signiﬁcant difference. A similar
trend for protective efﬁcacy was generally seen for other
subgroup categories examined in other prespeciﬁed sub-
group analyses, except for the subgroup of participants
aged 10–19 years in the LO-3 group (Table 3).
Safety
Both laninamivir octanoate regimens were well tolerated.
The most common adverse events were nasopharyngitis
(2.2 % in the LO-2 group, 3.3 % in the LO-3 group, and
2.5 % in the placebo group) and upper respiratory tract
inﬂammation (2.0 % in the LO-2 group, 1.3 % in the
LO-3 group, and 0.9 % in the placebo group). The
incidences of adverse events were 13.4 % (74/552),
13.0 % (72/553), and 11.6 % (65/559) in the LO-2, LO-
3, and placebo groups, respectively. The incidence in
each of the laninamivir octanoate group was similar to
that in the placebo group. The incidences of adverse
events considered by the investigator to be drug-related
were 3.1 % (17/552), 4.7 % (26/553), and 2.7 % (15/
559) in the LO-2, LO-3, and placebo groups, respec-
tively. All the adverse events were regarded as being
mild or moderate in severity. No deaths or other serious
adverse events were reported.
Discussion
This trial demonstrated that the inhalation of 20 mg of
laninamivir octanoate once daily for 2 or 3 days was
effective for preventing the development of inﬂuenza in
household contacts. Laninamivir octanoate appears to be
effective for preventing the transmission of inﬂuenza virus
as well as the development of inﬂuenza illness, since lan-
inamivir octanoate signiﬁcantly reduced the proportion of
participants with symptomatic inﬂuenza and the proportion
J Infect Chemother (2013) 19:740–749 743
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of participants infected with inﬂuenza virus, compared with
the placebo. In addition, the proportions of participants
with clinical inﬂuenza were similar between the LO-2 and
LO-3 groups, and inhalation of 20 mg of laninamivir
octanoate once daily for 2 days was preferable for the
lower dosing frequency.
The protective efﬁcacy (LO-2, 77.0 %) after the
administration of laninamivir octanoate once daily for only
2 days was comparable to that obtained using oseltamivir
[5, 6] or zanamivir [8, 9]. This protective effect from fewer
doses of laninamivir octanoate than oseltamivir or za-
namivir can be explained by the pharmacokinetic
Fig. 1 Participant ﬂow chart. LO-2 20 mg of laninamivir octanoate
administered once daily for 2 days; LO-3 20 mg of laninamivir
octanoate administered once daily for 3 days; FAS the full analysis
set, FASII the full analysis set index-infected, FASIINAB the full
analysis set index-infected virus-negative at baseline. aOne participant
who was allocated to the placebo group received 20 mg of
laninamivir octanoate for 3 days. This participant was included in
the originally allocated group in the full analysis set but was analyzed
according to the actually administered treatment in the safety analysis
set. A total of 1664 participants were included in the safety analysis
set (552 participants in the LO-2 group, 553 in the LO-3 group, and
559 in the placebo group)
744 J Infect Chemother (2013) 19:740–749
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characteristics of laninamivir octanoate, since a consider-
ably high laninamivir concentration persisted in the lungs
for 10 days after a single inhaled dose [17]. In the previous
trial, the inhalation of laninamivir octanoate once a week
(Days 1 and 8) seemed to be somewhat effective for post-
exposure prophylaxis of inﬂuenza in household contacts,
but the protective efﬁcacy was not sufﬁcient. However, in
the present trial, the inhalation of laninamivir octanoate
once daily for 2 days demonstrated a signiﬁcant protective
efﬁcacy in household contacts. Thus, the second inhaled
administration of laninamivir octanoate effectively
contributed to the prevention of inﬂuenza in household
members. The inhalation of laninamivir octanoate once
daily for 2 days has the advantages of convenience and
compliance over oseltamivir or zanamivir.
In this trial, we could not fully evaluate the efﬁcacy for
participants whose index patients were infected with
inﬂuenza A(H1N1)pdm09, seasonal inﬂuenza A(H1N1), or
inﬂuenza B viruses, since most of the index patients were
infected with inﬂuenza A(H3N2) virus. Non-clinical study
results have shown that laninamivir octanoate is effective
against inﬂuenza A(H1N1)2009, seasonal inﬂuenza
Table 1 Demographic and baseline characteristics of participants included in the full analysis set index-infected virus-negative at baseline
Characteristic LO-2
(N = 487)
LO-3
(N = 486)
Placebo
(N = 478)
Characteristic LO-2
(N = 487)
LO-3
(N = 486)
Placebo
(N = 478)
Participants Index patientsa
Age Age
Mean ± SD (years) 34.5 ± 9.7 33.8 ± 10.2 34.0 ± 9.2 Mean ± SD (years) 7.5 ± 3.5 7.5 ± 4.3 7.7 ± 5.3
Group (years) [no. (%)] Group (years) [no. (%)]
10–14 43 (8.8) 58 (11.9) 43 (9.0) 0–4 98 (20.1) 96 (19.8) 89 (18.6)
15–19 18 (3.7) 9 (1.9) 11 (2.3) 5–9 264 (54.2) 281 (57.8) 275 (57.5)
20–29 36 (7.4) 37 (7.6) 42 (8.8) 10–14 116 (23.8) 97 (20.0) 99 (20.7)
30–39 241 (49.5) 235 (48.4) 264 (55.2) 15–19 6 (1.2) 5 (1.0) 7 (1.5)
40–49 144 (29.6) 141 (29.0) 113 (23.6) 20–29 3 (0.6) 4 (0.8) 3 (0.6)
50–59 4 (0.8) 5 (1.0) 4 (0.8) 30–39 0 (0.0) 2 (0.4) 2 (0.4)
60– 1 (0.2) 1 (0.2) 1 (0.2) 40–49 0 (0.0) 0 (0.0) 2 (0.4)
Sex [no. (%)] 50–59 0 (0.0) 1 (0.2) 0 (0.0)
Female 427 (87.7) 423 (87.0) 422 (88.3) 60– 0 (0.0) 0 (0.0) 1 (0.2)
Male 60 (12.3) 63 (13.0) 56 (11.7) Sex [no. (%)]
Time to ﬁrst dose after onset in index patients Female 238 (48.9) 236 (48.6) 219 (45.8)
Mean ± SD (h) 21.6 ± 11.3 23.0 ± 12.5 22.5 ± 12.6 Male 249 (51.1) 250 (51.4) 259 (54.2)
Group (h) [no. (%)] Rapid diagnostic test [no. (%)]
0–12 101 (20.7) 101 (20.8) 99 (20.7) Positive 487 (100.0) 486 (100.0) 478 (100.0)
12–24 207 (42.5) 181 (37.2) 189 (39.5) Laboratory-conﬁrmed inﬂuenza infection
24–36 122 (25.1) 123 (25.3) 117 (24.5) Virus Type and Subtype [no. (%)]
36–48 54 (11.1) 80 (16.5) 70 (14.6) 2009H1N1 0 (0.0) 0 (0.0) 0 (0.0)
48– 3 (0.6) 1 (0.2) 3 (0.6) H1N1 0 (0.0) 0 (0.0) 0 (0.0)
Relationship to index patient [no. (%)] H3N2 443 (91.0) 440 (90.5) 434 (90.8)
Parent 423 (86.9) 413 (85.0) 415 (86.8) B 43 (8.8) 44 (9.1) 43 (9.0)
Sibling 62 (12.7) 69 (14.2) 54 (11.3) Mixed 1 (0.2) 2 (0.4) 1 (0.2)
Child 0 (0.0) 1 (0.2) 1 (0.2) Treatment of inﬂuenza [no. (%)]
Spouse 1 (0.2) 0 (0.0) 3 (0.6) Oseltamivir 373 (76.6) 389 (80.0) 372 (77.8)
Other 1 (0.2) 3 (0.6) 5 (1.0) Zanamivir 113 (23.2) 94 (19.3) 101 (21.1)
High-riskb [no. (%)] 14 (2.9) 10 (2.1) 20 (4.2) Other 1 (0.2) 3 (0.6) 5 (1.0)
LO-2 20 mg of laninamivir octanoate administered once daily for 2 days, LO-3 20 mg of laninamivir octanoate administered once daily for
3 days, SD standard deviation, 2009H1N1 inﬂuenza A(H1N1)pdm09, H1N1 seasonal inﬂuenza A(H1N1), H3N2 inﬂuenza A(H3N2), B inﬂuenza
B
a More than one participant could be enrolled for each index patient. In this case, the index patient was counted once for each household contact
who was enrolled. Actually, 1278 index patients (FASIINAB) were enrolled. In this table, the ‘‘N’’ is identical for household contacts and index
patients in each treatment group. This is due to ‘‘reduplicative’’ counting
b Age C65 years or with concomitant illness (immunodeﬁciency, metabolic disorder, chronic respiratory illness, chronic renal impairment, or
chronic heart disease)
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Table 2 Protective effects of laninamivir octanoate against inﬂuenza infection
Outcome LO-2 (N = 487) LO-3 (N = 486) Placebo (N = 478)
No./total (%) P valuea Protective efﬁcacyb
(95 %CI)
No./total
(%)
P-valuea Protective efﬁcacyb
(95 % CI)
No./total (%)
Primary endpoint (FASIINAB)
Clinical inﬂuenzac 19/487 (3.9) \0.001 77.0 (62.7 to 85.8) 18/486 (3.7) \0.001 78.1 (64.1 to 86.7) 81/478 (16.9)
– – – – 1.00d 5.1 (-78.7 to 49.6)d –
Secondary endpoints (FASIINAB)
Symptomatic inﬂuenzae 33/487 (6.8) \0.001 67.6 (53.0 to 77.7) 32/486 (6.6) \0.001 68.5 (54.1 to 78.4) 100/478 (20.9)
Asymptomatic inﬂuenzaf 17/487 (3.5) 0.41 24.2 (-41.0 to 59.2) 18/486 (3.7) 0.52 19.5 (-48.1 to 56.3) 22/478 (4.6)
Inﬂuenza infectiong 50/487 (10.3) \0.001 59.8 (45.5 to 70.3) 50/486 (10.3) \0.001 59.7 (45.4 to 70.3) 122/478 (25.5)
Other endpoints
Clinical inﬂuenzac in FAS 29/550 (5.3) \0.001 74.2 (61.9 to 82.5) 31/550 (5.6) \0.001 72.4 (59.7 to 81.1) 114/558 (20.4)
Clinical inﬂuenzac in FASII 29/543 (5.3) \0.001 74.4 (62.2 to 82.7) 31/539 (5.8) \0.001 72.5 (59.8 to 81.1) 114/546 (20.9)
LO-2 20 mg of laninamivir octanoate administered once daily for 2 days, LO-3 20 mg of laninamivir octanoate administered once daily for 3 days, CI conﬁdence interval, FASIINAB the full
analysis set index-infected virus-negative at baseline, FAS the full analysis set, FASII the full analysis set index-infected
a Analyzed using Fisher exact test
b Protective efﬁcacy (relative risk reduction) = 100 9 (1 - LO-2 or LO-3/Placebo)
c Clinical inﬂuenza was deﬁned as the presence of laboratory-conﬁrmed inﬂuenza, an axillary temperature of at least 37.5 C, and at least two inﬂuenza symptoms
d Compared with LO-2
e Symptomatic inﬂuenza, including clinical inﬂuenza, was deﬁned as laboratory-conﬁrmed inﬂuenza accompanied by an axillary temperature of at least 37.5 C or at least one inﬂuenza
symptom
f Asymptomatic inﬂuenza was deﬁned as laboratory-conﬁrmed inﬂuenza accompanied by an axillary temperature of lower than 37.5 C and no inﬂuenza symptoms
g Inﬂuenza infection was deﬁned as laboratory-conﬁrmed inﬂuenza, regardless of the presence or absence of an axillary temperature of at least 37.5 C or an inﬂuenza symptom
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A(H1N1), and inﬂuenza B viruses [10, 11]. The prophy-
lactic efﬁcacy of laninamivir octanoate against these virus
types should be further evaluated.
This trial excluded children younger than 10 years of
age. However, considering the fact that a single inhaled
dose of 20 or 40 mg of laninamivir octanoate was sufﬁcient
to treat children with seasonal inﬂuenza, including illnesses
caused by oseltamivir-resistant viruses, and that the treat-
ment was well-tolerated [13], laninamivir octanoate might
be a valuable prophylactic agent against inﬂuenza for
Fig. 2 Cumulative number of
participants with clinical
inﬂuenza according to
observation day in the full
analysis set index-infected
virus-negative at baseline. LO-2
20 mg of laninamivir octanoate
administered once daily for
2 days, LO-3 20 mg of
laninamivir octanoate
administered once daily for
3 days
Table 3 Subgroup analyses for clinical inﬂuenza in the full analysis set index-infected virus-negative at baseline
Subgroup LO-2 LO-3 Placebo
No./total (%) P valuea Protective efﬁcacyb
(95 % CI)
No./total (%) P valuea Protective efﬁcacyb
(95 % CI)
No./total (%)
Virus type and subtype
H3N2 16/443 (3.6) \0.001 79.1 (64.7 to 87.6) 14/440 (3.2) \0.001 81.6 (67.9 to 89.4) 75/434 (17.3)
B 3/43 (7.0) 0.48 50.0 (-87.1 to 86.6) 4/44 (9.1) 0.52 34.8 (-114.9 to 80.2) 6/43 (14.0)
Age (years)
10–19 2/61 (3.3) 0.25 64.6 (-75.1 to 92.8) 7/67 (10.4) 1.00 -12.8 (-235.7 to 62.1) 5/54 (9.3)
20–29 1/36 (2.8) 0.03 85.4 (-11.1 to 98.1) 3/37 (8.1) 0.20 57.4 (-48.7 to 87.8) 8/42 (19.0)
30–39 12/241 (5.0) \0.001 74.2 (52.8 to 85.9) 8/235 (3.4) \0.001 82.4 (63.6 to 91.5) 51/264 (19.3)
40 4/149 (2.7) \0.001 81.4 (46.1 to 93.6) 0/147 (0.0) \0.001 100.0 17/118 (14.4)
Sex
Female 17/427 (4.0) \0.001 77.3 (62.2 to 86.4) 15/423 (3.5) \0.001 79.8 (65.4 to 88.2) 74/422 (17.5)
Male 2/60 (3.3) 0.08 73.3 (-23.0 to 94.2) 3/63 (4.8) 0.18 61.9 (-40.3 to 89.7) 7/56 (12.5)
Time from onset of inﬂuenza in index patient to completion of ﬁrst study treatment (h)
\24 13/308 (4.2) \0.001 73.0 (51.0 to 85.1) 13/282 (4.6) \0.001 70.5 (46.5 to 83.7) 45/288 (15.6)
C24 6/179 (3.4) \0.001 82.3 (59.0 to 92.4) 5/204 (2.5) \0.001 87.1 (67.7 to 94.8) 36/190 (18.9)
High-riskc 1/14 (7.1) 0.37 64.3 (-186.5 to 95.5) 0/10 (0.0) 0.27 100.0 4/20 (20.0)
LO-2 20 mg of laninamivir octanoate administered once daily for 2 days, LO-3 20 mg of laninamivir octanoate administered once daily for
3 days, CI conﬁdence interval, H3N2 inﬂuenza A(H3N2), B inﬂuenza B
a Analyzed using Fisher exact test
b Protective efﬁcacy (relative risk reduction) = 100 9 (1 - LO-2 or LO-3/Placebo)
c Age C65 years or with concomitant illness (immunodeﬁciency, metabolic disorder, chronic respiratory illness, chronic renal impairment, or
chronic heart disease)
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children. In addition, our trial excluded participants who
came in contact with the index patients[48 h after the
onset of illness. Postexposure chemoprophylaxis for per-
sons should only be used when antivirals can be started
within 48 h of the most recent exposure, as recommended
by the Centers for Disease Control and Prevention [2, 18].
Generally, antiviral chemoprophylaxis should be con-
sidered for persons with a high risk of developing com-
plications from inﬂuenza, such as the elderly (65 years or
older), persons with complications (chronic respiratory
illness, metabolic disorders including diabetes mellitus,
chronic heart disease, or immunodeﬁciency), or pregnant
women. Further research regarding the prophylactic
administration of laninamivir octanoate in high-risk groups
is needed.
In conclusion, the inhalation of 20 mg of laninamivir
octanoate once daily for 2 or 3 days provided protection
against inﬂuenza in household contacts. Our ﬁndings
indicated that prophylaxis with laninamivir octanoate is an
effective option for the post-exposure prophylaxis of
inﬂuenza. Laninamivir octanoate is approved for the
treatment of inﬂuenza and is widely used in clinical prac-
tice in Japan. In previous treatment trials [12–14] and post-
marketing surveillance [19], no cases of bronchospasm or
respiratory function deterioration have been reported,
though laninamivir octanoate is an inhalant. Laninamivir
octanoate appears to be a safe and useful agent for the
prevention of inﬂuenza, as long as it is inhaled
appropriately.
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